Literature DB >> 23856330

Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage.

Valérie Delbos1, Ludovic Lemée, Jacques Bénichou, Gilles Berthelot, Ala-Eddine Deghmane, Jean-Philippe Leroy, Estelle Houivet, Eva Hong, Muhamed-Kheir Taha, François Caron.   

Abstract

The aim of the study was to analyze the impact of MenBvac, an outer membrane vesicle (OMV) vaccine against P1.7,16 strains, on meningococcal carriage. During a B:14:P1.7,16/ST-32 outbreak in Normandy (France), children aged 1-7 years were randomly selected to participate in the study. Among the 1082 volunteers, there were 17 Neisseria meningitidis carriers (carriage rate of 1.57%). MenBvac vaccination appeared associated with lower carriage rate, i.e., 0.31% among the vaccinated children versus 2.10% among the non-vaccinated (p=0.03). The beneficial effect on carriage was observed regardless of the strain serogroup. OMV-vaccinated mice also showed reduction of bacterial acquisition of OMV-homolog and hererolog strains in respiratory pathways after intranasal challenge. These results suggest that meningococcal OMV-based vaccines reduce meningococcal carriage and may hence confer herd immunity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carriage; Meningococci; Outbreak; Outer membrane vesicle vaccine

Mesh:

Substances:

Year:  2013        PMID: 23856330     DOI: 10.1016/j.vaccine.2013.06.080

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Authors:  Rolando Pajon; Carolyn M Buckwalter; Kay O Johswich; Scott D Gray-Owen; Dan M Granoff
Journal:  Vaccine       Date:  2015-02-04       Impact factor: 3.641

2.  Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.

Authors:  Gary M Ginsberg; Colin Block; Chen Stein-Zamir
Journal:  Int J Public Health       Date:  2016-04-22       Impact factor: 3.380

3.  Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.

Authors:  Henju Marjuki; How-Yi Chang; Nadav Topaz; Melissa J Whaley; Jeni Vuong; Alexander Chen; Laurel T Jenkins; Fang Hu; Susanna Schmink; Adam C Retchless; Jennifer D Thomas; Anna M Acosta; Lucy A McNamara; Heidi M Soeters; Sarah Mbaeyi; Xin Wang
Journal:  mBio       Date:  2021-05-18       Impact factor: 7.867

Review 4.  The Therapeutic Benefit of Bacterial Membrane Vesicles.

Authors:  Natalie J Bitto; Maria Kaparakis-Liaskos
Journal:  Int J Mol Sci       Date:  2017-06-16       Impact factor: 5.923

Review 5.  Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature.

Authors:  Paul Balmer; Cynthia Burman; Lidia Serra; Laura J York
Journal:  Hum Vaccin Immunother       Date:  2018-05-09       Impact factor: 3.452

6.  Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK.

Authors:  J Huels; K M Clements; L J McGARRY; G J Hill; J Wassil; S Kessabi
Journal:  Epidemiol Infect       Date:  2013-11-28       Impact factor: 4.434

7.  The role of pediatricians as key stakeholders in influencing immunization policy decisions for the introduction of meningitis B vaccine in Canada: The Ontario perspective.

Authors:  Hirotaka Yamashiro; Nora Cutcliffe; Simon Dobson; David Fisman; Ronald Gold
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Jul-Aug       Impact factor: 2.471

Review 8.  Extracellular Vesicles: Role in Inflammatory Responses and Potential Uses in Vaccination in Cancer and Infectious Diseases.

Authors:  João Henrique Campos; Rodrigo Pedro Soares; Kleber Ribeiro; André Cronemberger Andrade; Wagner Luiz Batista; Ana Claudia Torrecilhas
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

Review 9.  Global practices of meningococcal vaccine use and impact on invasive disease.

Authors:  Asad Ali; Rabab Zehra Jafri; Nancy Messonnier; Carol Tevi-Benissan; David Durrheim; Juhani Eskola; Florence Fermon; Keith P Klugman; Mary Ramsay; Samba Sow; Shao Zhujun; Zulfiqar Bhutta; Jon Abramson
Journal:  Pathog Glob Health       Date:  2014-01       Impact factor: 2.894

10.  Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.

Authors:  Hannah Christensen; Caroline L Trotter; Matthew Hickman; W John Edmunds
Journal:  BMJ       Date:  2014-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.